Should I buy Healthpeak Properties (DOC) stock or is it too late?

Healthpeak Properties · Real Estate · price $19

See the full Healthpeak Properties (DOC) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Cantor Fitzgerald — 71% of its targets hit on this sector (17 calls tested). It aims for $23 (+21 %), call made on August 7, 2026, maturing on August 7, 2027 (68 d ago).

The 3 reliable analysts $23+21 %

The 10 other firms $22+16 %

How to read it: the 3 reliable firms are not filtered by optimism — 3 aim above the price, 0 below, hence their $23 median. “The 10 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Healthpeak Properties

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Scotiabank	40 %	+0.9 %	5	$21 +11%
Mizuho	20 %	-1.8 %	5	$24 +26%
Wedbush	0 %	-12.3 %	5	$22 +16%
RBC Capital	0 %	-19.6 %	6	$24 +26%

In short — Should you invest in Healthpeak Properties? Is it too late, still worth it? Analysts are split (31% buy, median target $22, i.e. +16%), and the most reliable on DOC targets even higher. But the valuation is stretched (P/E ~54). We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Median price target $22, i.e. +16% from the current price ($19).
The most reliable firm on DOC, JP Morgan (50% hit rate, 2 scored calls), targets $21 (call made on June 24, 2026, maturing on June 24, 2027) (+11%) in its most recent call.
Pays a dividend (5.7% yield) — regular income on top of potential upside.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 13 ratings, 9 are neutral.
High valuation (P/E ~54): strong growth is already "priced in", leaving little room for error.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on DOC

Median target $22 (+16%) · 13 ratings · Hold consensus

Strong Buy00%

Buy431%

Hold969%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Healthpeak Properties now?

We won't decide for you. The facts: 31% of analysts rate it a buy, median target $22 (+16%), and JP Morgan (most reliable on DOC, 50%) targets $21. Weigh that against valuation (P/E ~54). This is not personalized advice.

Is it too late to invest in Healthpeak Properties?

Not according to analysts: the median target ($22) is still +16% above the current price ($19) (most reliable on DOC: JP Morgan, 50%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Healthpeak Properties still worth investing in?

It depends on the gap between the price ($19) and its estimated value: analysts target $22 on median (+16%), with 31% buys (most reliable on DOC: JP Morgan, 50%). Cross-check with their real reliability on DOC and the cautions above. Information, not advice.

What's the main risk in buying DOC?

The consensus is not unanimous: of 13 ratings, 9 are neutral.

→ Go deeper: the full Healthpeak Properties profile (consensus, analyst reliability, price target, performance).